Trial Profile

A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant human thyroid stimulating hormone-Suzhou Zelgen Biopharmaceuticals (Primary) ; Iodine radioactive
Indications Carcinoma; Thyroid cancer
Focus Therapeutic Use
Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

20 Oct 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
20 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
22 Mar 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com